Improved bioavailability of buccal nanoemulsion vitamin D compared to conventional oral supplementation in patients with inflammatory bowel disease: a randomized controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F25%3A10002843" target="_blank" >RIV/27661989:_____/25:10002843 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/25:00082391 RIV/00064190:_____/25:10001415

Výsledek na webu

<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1649677/full" target="_blank" >https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1649677/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fmed.2025.1649677" target="_blank" >10.3389/fmed.2025.1649677</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Improved bioavailability of buccal nanoemulsion vitamin D compared to conventional oral supplementation in patients with inflammatory bowel disease: a randomized controlled trial

Popis výsledku v původním jazyce

Objectives The absorption of conventional cholecalciferol may be impaired in patients with inflammatory bowel disease (IBD). The bioavailability and optimal dosing of buccally absorbable nanoemulsion vitamin D in this population remain unclear. This study aimed to compare the effects of buccal nanoemulsion and conventional oral vitamin D supplementation on serum 25-hydroxyvitamin D (25OHD) levels in patients with IBD. Methods This was an open-label randomized trial. Patients with IBD were assigned to receive cholecalciferol in an oil emulsion at a dose of 14 000 IU weekly (GTTS) and orally absorbed cholecalciferol at dose 4000 IU twice a week (SPRAY) for 12-16 weeks during the winter months. Plasma 25OHD levels were measured at baseline and after the supplementation period. Results A total of 120 patients were analyzed. Among 75 subjects with CD and 45 with UC, 27% had active disease, and 24% of the Crohn&apos;s disease patients had undergone ileocecal resection. The initial mean 25OHD level was 65.9 +/- 21.0 nmol/l in the SPRAY group and 59.1 +/- 27.7 nmol/l in the GTTS group. A similar increase of 9.3 +/- 26.8 nmol/l (GTTS) and 9.2 +/- 27.7 nmol/l (SPRAY) in 25OHD levels occurred in both groups, with similar variations. The proportion of subjects with normal and sub-normal levels following the substitution was comparable. The change in 25OHD level correlated negatively only with the baseline 25OHD level (p &lt; 0.02) among all monitored variables. Conclusion In IBD patients, the sufficient supplementation dose of the orally absorbable cholecalciferol is half that of the conventional oil emulsion (1143 IU/day vs. 2000 IU/day). Variable intestinal absorption is not a factor explaining inter-individual differences in 25OHD levels using a conventional vitamin D emulsion.

Název v anglickém jazyce

Improved bioavailability of buccal nanoemulsion vitamin D compared to conventional oral supplementation in patients with inflammatory bowel disease: a randomized controlled trial

Popis výsledku anglicky

Objectives The absorption of conventional cholecalciferol may be impaired in patients with inflammatory bowel disease (IBD). The bioavailability and optimal dosing of buccally absorbable nanoemulsion vitamin D in this population remain unclear. This study aimed to compare the effects of buccal nanoemulsion and conventional oral vitamin D supplementation on serum 25-hydroxyvitamin D (25OHD) levels in patients with IBD. Methods This was an open-label randomized trial. Patients with IBD were assigned to receive cholecalciferol in an oil emulsion at a dose of 14 000 IU weekly (GTTS) and orally absorbed cholecalciferol at dose 4000 IU twice a week (SPRAY) for 12-16 weeks during the winter months. Plasma 25OHD levels were measured at baseline and after the supplementation period. Results A total of 120 patients were analyzed. Among 75 subjects with CD and 45 with UC, 27% had active disease, and 24% of the Crohn&apos;s disease patients had undergone ileocecal resection. The initial mean 25OHD level was 65.9 +/- 21.0 nmol/l in the SPRAY group and 59.1 +/- 27.7 nmol/l in the GTTS group. A similar increase of 9.3 +/- 26.8 nmol/l (GTTS) and 9.2 +/- 27.7 nmol/l (SPRAY) in 25OHD levels occurred in both groups, with similar variations. The proportion of subjects with normal and sub-normal levels following the substitution was comparable. The change in 25OHD level correlated negatively only with the baseline 25OHD level (p &lt; 0.02) among all monitored variables. Conclusion In IBD patients, the sufficient supplementation dose of the orally absorbable cholecalciferol is half that of the conventional oil emulsion (1143 IU/day vs. 2000 IU/day). Variable intestinal absorption is not a factor explaining inter-individual differences in 25OHD levels using a conventional vitamin D emulsion.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30218 - General and internal medicine

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in Medicine

ISSN

—

e-ISSN

2296-858X

Svazek periodika

12

Číslo periodika v rámci svazku

AUG

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

8

Strana od-do

nestránkováno

Kód UT WoS článku

001567852600001

EID výsledku v databázi Scopus

2-s2.0-105015182917